Chime Biologics Announces Strategic Collaboration with TNAX Biopharma, Marking Its First Partnership in Japan

December 9, 2025, Tsukuba, Japan and Wuhan, China - TNAX Biopharma, a biopharmaceutical company focused on the development and commercialization of novel antibody therapeutics that address unmet medical needs of patients with intractable diseases, and Chime Biologics, a leading global CDMO that enables its partners' success in biologics, announced a strategic collaboration for the development of TNAX103, a humanized anti-CD300A monoclonal antibody. This milestone marks Chime Biologics’ first project in Japan, reflecting the successful validation of its unique value proposition among innovative biotechs in the Japanese market.

A New Paradigm of Japan–China Biopharma Innovation

This collaboration brings together Japan’s scientific innovation and the world-leading efficiency of China’s biopharma development ecosystem, integrated seamlessly through Chime Biologics’ advanced platform and further empowered by the Chime Innovation Alliance.

Chime Biologics believes that this model will become a novel paradigm for the next era of biopharma R&D, reshaping how Japanese innovations accelerate to global markets and redefining Japan’s position in the global biopharma landscape.

About the Collaborative Project: TNAX103

The project focuses on TNAX103, a humanized anti-CD300A monoclonal antibody designed to promote efferocytosis and suppress inflammation. TNAX103 fundamentally targets the underlying mechanisms of ischemia-reperfusion injury (IRI) in acute kidney injury (AKI)—a condition associated with a mortality rate of approximately 50% and a significant risk factor contributing to the progression of chronic kidney disease (CKD). TNAX103 promotes the clearance of ischemia-induced dead cells and blocks the inflammatory cascade triggered by cell death. In addition to AKI models, pharmacological data demonstrate efficacy in acute ischemic mouse models such as stroke and spinal cord injury. TNAX103 has the potential for chronic diseases, such as inflammatory and autoimmune diseases, in which dead cells contribute to pathogenesis.

Chime Biologics will leverage its integrated biologics development platform, proven global quality system, and rapid development capabilities to support TNAX Biopharma in advancing TNAX103 toward clinical readiness.

Tak Mukohira, CEO of TNAX Biopharma, stated: “Chime Biologics is an outstanding partner with exceptional CMC expertise that will advance the global development of this groundbreaking asset. This agreement underscores the fact that TNAX Biopharma has been selected by Chime Biologics as a strategic partner for innovative biologics.”

Dr. Ichimaro Yamada (General Manager, R&D at TNAX Biopharma and VP of the Association for Promoting Drug Development) added: “We are confident that Chime Biologics’ extensive expertise in biologics manufacturing will significantly accelerate the development of TNAX103, enabling us to deliver this potentially life-changing therapy to patients around the world as quickly as possible.”

“We are thrilled to embark on our first collaborative project in Japan with TNAX Biopharma,” said Dr. Jimmy Wei, CEO of Chime Biologics. “This partnership not only signifies the recognition of our platform by innovators in Japan, but also demonstrates the power of connecting Japan’s strong discovery capabilities with China’s unparalleled development efficiency. We believe this collaboration model will reshape the biopharma landscape across the APAC region and beyond, creating new opportunities for global innovation.”

About TNAX Biopharma Corporation

TNAX Biopharma Corporation is a biotech company founded at the University of Tsukuba. It is dedicated to developing novel antibody therapeutics to address the high unmet medical needs in patients with intractable diseases. The company develops biologics targeting immunoreceptors and their ligands that play significant roles in immunity and inflammation.

Under the scientific leadership of Professor Akira Shibuya, MD, Ph.D., co-founder and Chief Scientific Officer, TNAX Biopharma has established a leading position in the immunoreceptor space. TNAX Biopharma’s first asset, TNAX101A, an anti-CD226 monoclonal antibody (mAb), was initially licensed to IMIDomics, Inc. In July 2025, Formation Bio licensed worldwide rights to the program. TNAX101A has been renamed RVW101 and is currently being advanced by Formation Bio in autoimmune indications. The antibody targets CD226 (DNAM-1), an immune checkpoint involved in regulating several key immune cells. By blocking CD226’s interaction with CD112 and CD155, the antibody aims to suppress immune overactivation.

About Chime Biologics

Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologic medicines to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our innovative and state-of-the-art development and manufacturing capabilities and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. With over 500 skilled employees, we share a common goal to make cutting-edge biomedicines affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally. For more information, please visit www.chimebiologics.com.